SEC Tracker
Get the app

Bioverativ

Bioverativ Q2 FY17: revenue $289.1M

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Bioverativ reported for Q2 FY17, the quarter ended Jun 30, 2017, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$289.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$77.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$137.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR

View on EDGAR

Open in the app

Get an email when Bioverativ files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.